Previous 10 | Next 10 |
NeuroBo Pharmaceuticals Announces $14 Million Registered Direct Offering PR Newswire BOSTON , Oct. 1, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimod...
Sonoma Pharmaceuticals (NASDAQ:SNOA) +70% on product launch in U.S. and Europe Planet Green (NYSE:PLAG) +30%. ZIVO Bioscience (NASDAQ:ZIVO) +20%. Frequency Electronics (NASDAQ:FEIM) +17% wins contract from the Office of Naval Research for atomic clock development AGM Group...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the term “technology” often brings to mind the broader digitalization movement, tech actually has the most potential in healthcare. Thanks to groundbreaking innovations, we now know much more about the h...
Gainers: Innate Pharma (NASDAQ:IPHA) +32%, Tiziana Life Sciences (NASDAQ:TLSA) +16%, Verrica Pharmaceuticals (NASDAQ:VRCA) +12%, NeuroBo Pharmaceuticals (NASDAQ:NRBO) +12%, Scopus BioPharma (NASDAQ:SCPS) +11%. Losers: Assembly Biosciences (NASDAQ:ASMB) ...
Plus Therapeutics (NASDAQ:PSTV) +22% on manufacturing deal for Rhenium-186 NanoLiposome Innate Pharma (NASDAQ:IPHA) +17% Monalizumab and ANKET™ data will be presented at ESMO 2021 virtual Congress ChargePoint Holdings (NYSE:CHPT) +16% on Q2 earnings. Tiziana Life Science...
NeuroBo Pharmaceuticals (NASDAQ:NRBO): Q2 GAAP EPS of -$0.18 misses by $0.03. Cash and Cash Equivalents were $9.5 million as of June 30, 2021, compared with $10.1 million as of December 31, 2020. Press Release For further details see: NeuroBo Pharmaceuticals EPS misses by $0.03
NeuroBo Pharmaceuticals Reports Second Quarter 2021 Financial Results PR Newswire BOSTON , Aug. 16, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal ...
Seres Therapeutics (MCRB) -57% after mid-stage ulcerative colitis study fails main goal.Jupiter Wellness (JUPW) -24% after raises $32.5M capital via stock and warrants offering.TRACON Pharmaceuticals (TCON) -23% after securing $15M capital raise.NETGEAR (NTGR)...
Gainers: Chembio Diagnostics (CEMI) +195%, NeuroMetrix (NURO) +143%, TRxADE HEALTH (MEDS) +40%, TransCode Therapeutics (RNAZ) +24%, Cassava Sciences (SAVA) +20%.Losers: NeuroBo Pharmaceuticals (NRBO) -19%, Healthcare Services (HCSG) -11%, ...
Staffing 360 Solutions, Inc. (STAF) -19% after pricing $7.58M registered direct offering.NeuroBo Pharmaceuticals, Inc. (NRBO) -13%.Nova LifeStyle, Inc. (NVFY) 2%.Aehr Test Systems (AEHR) -7%.Ardelyx, Inc. (ARDX) -6%.TD Holdings, Inc. (GLG) -5%. For further details see: Ardelyx...
News, Short Squeeze, Breakout and More Instantly...
NeuroBo Pharmaceuticals Inc. Company Name:
NRBO Stock Symbol:
NASDAQ Market:
NeuroBo Pharmaceuticals Inc. Website:
NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 PR Newswire CAMBRIDGE, Mass. , July 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transfo...
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Asce...
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon ...